PROM1 and colorectal carcinoma: we evaluated the CD133+ cell subpopulation in CRC cells, the results show TAS102 or Regorafenib monotherapy attenuates CD133+ subpopulation in CRC cells, the inhibitory effect of TAS102 upon CD133+ subpopulation is significant in HCT116, LS513 and HT29 cells, compared with regorafenib monotherapy.